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Rationale PROTECT DC examines whether stroke navigators
can improve cardiovascular risk factors in urban underserved
individuals newly hospitalized for stroke or ischemic attack.
Within one-year of hospital discharge, up to one-third of
patients no longer adhere to secondary prevention behaviors.
Adherence rates are lower in minority-underserved groups,
contributing to health disparities. In-hospital programs in-
crease use of stroke prevention therapies but may not be as
successful in underserved individuals. In these groups, low
literacy, limited healthcare access, and sparse community
resources may reduce adherence. Lay community health
workers (navigators) improve adherence in other illnesses
through education and assisting in overcoming barriers to
achieving desired health behaviors and obtaining needed
healthcare services.
Aims and design PROTECT DC is a Phase II, single-blind,
randomized, controlled trial comparing in-hospital education
plus stroke navigators to usual care. Atherogenic ischemic
stroke and transient ischemic attack survivors are recruited
from Washington, DC hospitals. Navigators meet with parti-
cipants during the index hospitalization, perform home visits,
and meet by phone. They focus on stroke education, medica-
tion compliance, and overcoming practical barriers to adher-
ence. The interventions are driven by the theories of reasoned
action and planned behavior.
Study outcomes The primary dependent measure is a sum-
mary score of four objective measures of stroke risk factor
control: systolic blood pressure, low-density lipoprotein, he-
moglobin Hb A1C, and antiplatelet agent pill counts. Second-
ary outcomes include stroke knowledge, exercise, dietary
modification, and smoking cessation.
Conclusion PROTECT DC will determine whether a Phase III
trial of stroke navigation for urban underserved individuals to
improve adherence to secondary stroke prevention behaviors
is warranted.
Key words: clinical trials, community health education, health
behavior, healthcare disparities, patient adherence, patient
compliance, secondary prevention, stroke
Introduction
Stroke remains the third leading cause of death and a leading
cause of adult disability in the United States. Healthcare costs
related to stroke total over US$50 billion per year in the United
States alone (1). Decades of research in cardiovascular risk
reduction have led to guidelines which, if optimally implemen-
ted, could prevent secondary stroke in 50–80% of patients (2).
Stroke is particularly prominent in urban underserved
populations. Sacco and colleagues found a 24-fold greater
stroke incidence in African Americans and a twofold increase
in Hispanics compared with Caucasians, with higher mortality
and lower three-year survival (3). At older ages, when stroke
mortality is the highest, the stroke mortality rate inDOI: 10.1111/j.1747-4949.2011.00654.x
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non-Hispanic Caucasians approached the stroke mortality
rate of African Americans (4). Compared with Caucasians,
minority groups suffered greater neurological impairment and
had poorer outcomes (5, 6).
Adherence to evidence-based therapies for the prevention of
ischemic stroke in patients remains inadequate. Even in the
general population, there is marked room for improvement in
the implementation of antithrombotics, lipid-lowering thera-
pies, antihypertensives, and smoking cessation counseling in
individuals who have experienced a cerebrovascular event (7),
particularly in African Americans. Superimposed are racial
differences in the use of aspirin and smoking cessation for
secondary prevention in veterans with coronary artery disease
(8). African Americans are less likely to receive a comprehensive
diagnostic evaluation compared with white patients and are less
likely to have a neurologist as their attending physician (9).
Several barriers to stroke prevention have been identified in
minority populations. A telephone study in African Americans
found that stroke knowledge was related to stroke risk factors
and that stress and inadequate finances were the most fre-
quently reported barriers (10). Schneider and colleagues found
that individuals with the highest risk and incidence of stroke,
including African Americans, were the least knowledgeable
about stroke warning signs and risk factors (11). Reasons for
these disparities likely include cultural, biological, and envir-
onmental factors (e.g. access to healthcare, education and
socioeconomic status (SES), variations in lifestyle, religious
and cultural beliefs, language barriers, and genetic factors).
Resolution of these disparities is urgently needed to improve
the health status of underserved communities.
Education of patients is one approach to overcoming these
issues, and in-hospital education has been emphasized by
many organizations. For example, the American Heart Asso-
ciation (AHA) ‘Get with the Guidelines’ effort (12) uses in-
hospital presentation of education materials about stroke and
management of cardiovascular risk factors (13). Other efforts
have increased the intensity of the patient’s in-hospital educa-
tion experience by incorporating a nurse educator into this
process. For example, the original PROTECT LA study (14)
used a nurse to educate a predominantly white high SES stroke
population who later self-reported increased adherence to
medications and other risk factor modification efforts (14, 15).
Other programs have demonstrated success in targeting
underserved populations. Rimmer et al. (16) evaluated a 12-
week health promotion intervention for a predominantly
black population with stroke. Improvements in total serum
cholesterol, cardiovascular fitness, and strength were achieved
compared with the control group. A related example of
coordinated care for stroke patients is STEPS CARE: A Post
Discharge Intervention to Improve Stroke Outcomes. STEPS
CARE was a randomized clinical trial (RCT) of a geriatrics-
based model of post acute care provided by a geriatrician and
advanced practice geriatrics nurse. Results of a preliminary
study showed improvements at three-months in a health and
function global end-point composed of five domains (17).
The overall aim of this project is to perform a Phase II RCT
designed to prepare for a Phase III assessment of whether
PROTECT DC (hospital-based initiation of secondary pre-
vention strategies coupled with stroke navigation) can sig-
nificantly reduce secondary vascular events (stroke, MI, and
vascular death) rates in an underserved population at high risk
for subsequent stroke or serious cardiovascular events. Health
navigators are lay health workers recruited from the commu-
nity to be served; they are trained and supervised by physicians,
nurses, social workers, or health educators (18). The goal of
navigation is to improve self-management of chronic diseases
and to reduce the barriers to healthcare. Since only 20% of
disease self-management skills are disease specific (19), we
expect that techniques developed in other conditions will be
relevant to stroke patients. Navigation is effective in increasing
compliance in primary care (20), diabetes (21, 22), cancer (23),
cardiovascular disease, HTN (24, 25), and asthma (26). Our
goals are to refine the intervention and gather data necessary to
design that Phase III trial.
Methods
Design
In this Phase II trial, a total of 250 participants admitted to four
acute care urban hospitals and one rehabilitation hospital for
atherogenic stroke are being randomized. In the experimental
arm, community-based ‘stroke navigators’ facilitate compli-
ance and health care access. The usual and customary care
control arm consists of the American Heart Association
(AHA) materials tailored for African Americans (‘Power to
End Stroke’ http://www.powertoendstroke.org) distributed
during hospitalization.
The primary dependent measure will be the percentage of
four objective markers of stroke risk that are normal one-year
after stroke onset. Effects on secondary behavioral goals will
also be evaluated; the eight PROTECT DC goals are listed in
Table 1. Vascular event rates will be measured to optimize study
methodology and inform sample size calculation for a sub-
sequent Phase III trial.
The National Rehabilitation Hospital is the coordinating
site and the Institutional Review Board (IRB) of record
is Georgetown University. PROTECT DC is designated a
Table 1 Primary PROTECT DC goals
Primary
goals
1. Compliance with prescribed antithrombotic therapy
confirmed by pill count





5. Compliance with smoking cessation
6. Compliance with American Heart Association diet
7. Compliance with exercise regimen
8. Stroke awareness
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minimal risk study. The study is funded by the National
Institute of Neurological Disorders and Stroke at the National
Institutes of Health and a supplemental grant from National
Center on Minority Health and Health Disparities.
Patient population
The study sample is intended to be representative of stroke
patients in the District of Columbia (DC), a region over-
represented in African Americans and low SES individuals. No
racial, ethnic, or gender groups are excluded. Participants are
recruited from the inpatient stroke services from five hospitals
that serve a majority of the stroke patients within DC:
Washington Hospital Center, Howard University Hospital,
Georgetown University Hospital, Providence Hospital and
National Rehabilitation Hospital (NRH). Potential partici-
pants are identified from emergency department and hospital
admission records; coordinators screen and consent partici-
pants (Fig. 1).
The sample consists of adults (age418) hospitalized within
30 days of an ischemic stroke or TIA due to atherogenic
cerebrovascular or cardiac disease. Ischemic stroke is defined as
rapidly developing clinical signs of focal disturbance of cere-
bral function lasting more than 24 h. In the case of TIA or
clinical stroke with no lesion visualized on neuroimaging, a
stroke neurologist confirms the diagnosis. Atherogenic stroke
is defined as large vessel, small vessel, or cryptogenic etiology
with at least one stroke risk factor (27). Persons with embolic
stroke due to atherogenic cardiac disease are also included.
Participants reside within DC or within five miles of the DC
border. A caregiver or interested party must be available if the
participant is moderately or severely disabled. To minimize
loss to follow-up, a sufficient number of collateral contacts
(more than three preferred) are required. Subjects must be
judged likely to return to community setting at completion of
postacute care.
Individuals are excluded if they have one or more of the
following:
 nonatherogenic cause of stroke or embolic stroke due to
nonatherogenic heart disease
 NIHSS 420
 any medical condition that would limit participation in
follow-up assessments
 baseline dementia per informant report (AD 8 (28)) or
screening assessment (Short Blessed Memory Orientation
Concentration Test (29)).
Randomization
Study participants are randomized to navigation or control in
a 1 : 1 ratio using a baseline adaptive randomization algorithm,
stratified by recruitment site. The algorithm uses Pearson’s w2
statistic to measure treatment imbalance in baseline NIHSS
(r6 vs. 46), age (r65 vs. 465) or gender (30, 31). A new
subject is randomly assigned with probability 075 to the group
that would achieve the best treatment balance among these
three characteristics. The first 12 participants in each site were
randomized with a fair coin, and their baseline characteristics
used to start the adaptive randomization. The randomization
algorithm is embedded in a web-based data management
application, and treatment assignments are available immedi-
ately upon baseline data entry. The inclusion/exclusion criteria
were incorporated into the application to ensure all rando-
mized patients are eligible. We chose to stratify randomization
based on the admitting hospital because of concerns that
differences in hospital practices and procedures could be a
source of systematic bias. These biases could stem from
differences in patient populations, acute management, post-




















phone calls years 2
through 4
Fig. 1 Study design.
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factors. Stratified randomization by hospital will minimize
these effects.
Experimental intervention
Participants randomized to the experimental arm initially meet
the stroke navigator as an inpatient; that same navigator becomes
the primary navigator for that participant during the one-year
intervention. At hospital discharge, the navigator ensures that
the patient has a participant handbook specific to the assigned
treatment group, tailored AHA educational materials, and
prescriptions. After discharge, the stroke navigator assesses
adherence and actively screens for barriers to medication
adherence and access to healthcare services. The navigators
also provide tailored health education regarding each of the
primary and secondary study goals namely medication compli-
ance, smoking cessation, AHA diet, physical activity/exercise and
stroke awareness. Interactions occur with a minimum of two
home visits and monthly phone calls. Many individuals need
more frequent contact to help resolve family and social barriers
to adherence that are identified. Techniques used include
motivational interviewing, application of the principles of health
behavior, and practical problem solving regarding issues such as
transportation, insurance, and fear of medication side effects.
Navigators interact with primary care doctors when necessary
and assist the participant in obtaining medications. Aside from
navigation, no additional resources are provided to participants
by the study. Navigators are supervised by a team of physicians,
health educators and social workers on a daily basis.
The PROTECT DC intervention is based on the Theories of
Reasoned Action and Planned Behavior (TRA, TPB) (32, 33).
Thus, navigators focus efforts on increasing the participant’s
behavioral intention toward taking medications, not simply
toward avoiding stroke. They also focus on increasing the
participant’s actual and perceived control over barriers to
adherence. The TRA/TPB model provides several targets for
improving medication compliance for secondary stroke pre-
vention. For example, education of the individual/family
caregivers/healthcare providers about medications’ beneficial
effects can tilt behavioral and normative beliefs more firmly
toward compliance. Motivation is likely to be highest imme-
diately after stroke, during the acute hospitalization. Educa-
tion about solutions to difficulties in taking medication and
assistance in elimination of barriers, increases the individual’s
perception of control over their situation, again increasing the
likelihood of adherence.
Control intervention: usual and customary care
The control intervention retains subjects while minimizing any
study-related impact on stroke prevention behaviors. The control
intervention is a standardized version of the usual and customary
care delivered at each hospital, and participants receive the same
tailored AHA materials as the experimental arm without navi-
gator input. Control subjects are provided with a participant
handbook specific to their study assignment. Control subjects are
contacted by phone monthly to confirm contact information and
to inquire about hospitalizations. If the participant requests
information, study staff mail relevant materials.
Blinding
Blinded raters obtain all follow-up data. Raters are supervised
by research staff outside the study; participants are instructed
not to reveal their treatment assignment. Vascular events,
rehospitalizations, and other clinical events are adjudicated
by a physician blinded to treatment assignment.
Baseline data
Trained study coordinators collect data regarding demo-
graphics, cognitive status (1), stroke type, and severity.
Table 2 Selected study assessments
Domain assessed Baseline 3-months 12 months
History and physical Medical status X
Vital signs Medical status, risk factor management X X X
Demographics Social and economic status X X X
NIH Stroke Scale Stroke severity X X X
Cognitive assessments X X X
Geriatric Depression Scale
Vascular Dementia Battery








Laboratory data (LDL, Hb A1C,) Risk factor management X X
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Prestroke functional status, health behaviors, and health beliefs
are also assessed. Selected baseline measurements can be found
in Table 2.
Primary outcome measures
The primary dependent measure is defined as the proportion of
four objective measures of stroke risk (SBP, LDL, Hb A1C, and
antiplatelet compliance documented by pill count) which are
within normal range (34) (Table 3) at the primary time point of
one-year. Compliance with antiplatelet agents is defined as pill
counts documenting use of 80% of prescribed medication (35).
Risk factors that are within normal limits at study enrollment
(e.g., normal prerandomization Hb A1C, LDL, SBP) will be
included in this analysis. These are physiological indicators of
stroke risk that are the targets of secondary stroke reduction
efforts and are intermediate steps to vascular event rate reduction.
Each is associated with medication compliance. A secondary
analysis of these measures will examine whether PROTECT DC
improved laboratory values by a clinically significant amount. For
those participants prescribed more than one antiplatelet agent,
compliance with each will be averaged into a single value.
Secondary outcome measures
Four stroke prevention behaviors were defined as secondary
goals of navigation (Table 3). The rate of primary vascular
events is another secondary measure; these are defined as the
documented occurrence of a subsequent stroke, MI, or vas-
cular death. Subjects and families will be contacted annually,
and medical records will be obtained where available for review
for blinded adjudication.
A secondary aim of the study is to assess the contribution of
health status, depression, cognition, SES, race and other factors
to the incidence of barriers and the rate of response to the study
interventions. Covariates collected to achieve this aim include
measures of disability (Barthel Index, Functional Indepen-
dence Measure and Lawton Instrumental ADL scale), social
participation (Activity Card Sort), and HR-QOL (SF-12 and
Stroke Impact Scale). These measures are collected at baseline
and at the one-year assessment by a blinded rater.
Ethics approval
All hospitals participating in this study have received IRB
approval; Georgetown University is the primary study IRB.
This trial is registered in clinicaltrials.gov (NCT00703274).
Data quality
Data quality control includes data checks that are built into a
data system to ensure the integrity of all data entered for each
study participant. These checks include range validator for
continuous variables, date and time pickers, and comparison
validators for consistency checks. In addition, the database
contains an audit trail of all data entries and edits with the
username and timestamp to monitor data entry and updates.
The web-based system also contains reports of form status
(completed, pending, or missing) and a report of key variables
to regularly check for data completeness and accuracy of these
data elements.
The second component of quality control process is a 100%
check of the baseline data in addition to annual 10% CRF
verification audits at each hospital to compare data in the study
database to data on CRF documents. The audit includes
verification of signed informed consents, checks for lab
procedures and records, verification of measurement tool
specifications, and checks that the clinical staff has up to
date study documentation available. Data errors are reported
to the study team for correction and a data entry error rate is
established after each audit.
Adverse event monitoring
Adverse events from this protocol are reported to the IRB.
Because navigation is a minimal risk intervention, adverse
events are monitored by the study investigators. A formal Data
Safety and Monitoring Board was not appointed.
Sample size
Sample size was determined based on a two-sided Wilcoxon
rank-sum test to compare the proportion of normal secondary
prevention stroke risk measures – a nonnormally distributed
outcome – in navigation and control groups. To achieve this, a
Table 3 Medication compliance goals
Medication goal Primary analysis: normalization Secondary analysis: clinically significant improvement
LDL LDLo100 mg/dl (o70 for very high risk) 1 mmol/dl
SBP SBPo120 mmHg SBP 10 mmHg reduction
Hb A1C o7% 1% reduction
Antiplatelet therapy Pill count documentation of 80% of prescribed
medications taken
Pill count documentation of 50% of prescribed
medications taken
Very high risk defined as patients who have established cardiovascular disease plus (1) multiple major risk factors (especially diabetes), (2) severe and
poorly controlled risk factors (especially continued cigarette smoking), (3) multiple risk factors of the metabolic syndrome (especially high triglycerides
(200 mg/dl) with low HDL cholesterol (40 mg/dl)), and (4) patients with acute coronary syndromes (34).
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sample size using Student’s t-statistic assuming a 005 sig-
nificance level and 80% power was first calculated, and then
adjusted based on the lower bound of the asymptotic relative
efficiency of the Wilcoxon rank-sum test relative to the t-test
(i.e. inflating the sample size by 157%) (36). Pilot data were
obtained from the PROTECT LA study (15) in which the mean
and standard deviation of the proportion of risk factor
compliance were 0690 and 021 in the intervention group,
and 0585 and 027 in the control group. The sample size
required is 198. However, a 20% dropout rate was assumed;
hence the target for enrollment is 230 participants.
Statistical analyses
Descriptive statistics will be computed for all study variables
including average follow-up time, retention rate, protocol
deviations, and violations, and will be compared by treatment
group. The primary analysis will be performed according to the
principle of intention to treat. Given that adaptive randomiza-
tion was used to assign patients to treatment or control, all
outcome analyses will be conducted by regression analyses
adjusted by the factors used in the adaptive randomization (37,
38). A nominal P value of 005 or less will be considered as
statistically significant in the primary analysis. Linear, logistic
or ordered logistic regression will be used as appropriate
depending on the distributions of the outcome measure.
Assessment of the fit of the models will be made using residual
plots for continuous variables and other measures of goodness
of fit such as the Hosmer Lemeshow test for categorical
response models.
A sequence of post hoc analysis will be conducted depending
on the results of the analyses of the primary outcome. If no
statistically significant difference is found between the inter-
vention groups, we will perform post hoc analyses to elucidate
whether the negative finding was likely due to true absence of a
treatment effect, or to design factors that resulted in an
underpowered study. Careful examination of these issues is
critical for considering the feasibility and utility of a future
Phase III trial of the PROTECT DC intervention. Analyses will
also be performed by subgroups, such as by race and age, in
order to determine whether there is any differential efficacy
found among any key subgroups of patients. If statistically
significant differences are found between treatment and con-
trol arms, we will conduct regression analyses. They will be
further adjusted by variables selected based on a combination
of clinical judgment and descriptive statistical findings com-
paring baseline characteristics between the control and PRO-
TECT DC intervention groups. These adjustments will help
describe the likely pathways by which the treatment influenced
outcome. Additional analyses will assess the patient’s adher-
ence to the intervention. Similar methods will be used to assess
the impact of the PROTECT DC intervention on secondary
behavioral goals.
Finally, we will conduct analyses to refine the inclusion/
exclusion criteria to identify those who cannot respond to the
intervention. This will help in planning a subsequent Phase III
trial of the PROTECT DC intervention. Specifically, we will
seek to identify baseline barriers such as poorer health status,
depression, SES, and other potential barriers that are asso-
ciated with less favorable response to the PROTECT DC
intervention at the one-year follow-up. Any barriers found
to be associated with a significantly reduced response to
intervention will be further examined at the patient level to
ensure that all the possible barriers/factors are considered.
Participant-specific barriers will be assessed by the stroke
navigators using various sources of information including
participants, caregivers, and the navigators themselves. These
analyses will be restricted to the intervention group because
some barrier interview questions are specifically related to this
group.
Summary
Improved secondary stroke prevention may reduce the fre-
quency of subsequent stroke or other vascular events. This
reduction is of great importance to society for reducing
disability and healthcare expenditures. Improving access to
healthcare for underserved populations will also reduce rates
of illness, disability, and poor quality of life. PROTECT DC will
determine whether navigation in combination with TRA can
improve health behavior and adherence to prevent future
strokes.
To date, PROTECT DC has recruited 162 participants across
five sites in Washington, DC. Findings will be reported in 2012.
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